Axonics reports first quarter 2023 financial results

Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended march 31, 2023. “our commercial team continues to execute at a high level, generating revenue growth of 46% year over year in the first quarter,” said raymond w. cohen, chief executive officer. “our sacral neuromodulation growth was d.
AXNX Ratings Summary
AXNX Quant Ranking